Montana Cannabis Licensing: Requirements, Application Process & Residency Rules

Executive Summary

Montana has implemented a new residency requirement for cannabis business licenses, leveraging federal prohibition as legal justification for restricting ownership to state residents. The Montana Department of Revenue's Cannabis Control Division adopted regulations in September 2026 requiring all cannabis license applicants to demonstrate Montana residency, marking a significant shift in the state's approach to market access since voters approved adult-use legalization in November 2020. The policy change affects cultivation, manufacturing, dispensary, and testing facility licenses across Montana's medical and adult-use programs. Industry observers expect the residency mandate to restrict multi-state operator expansion, protect existing Montana licensees from out-of-state competition, and potentially face legal challenges under the dormant Commerce Clause. The Montana Cannabis Control Division cited the continuing federal Schedule I classification of cannabis under the Controlled Substances Act as the legal foundation enabling state-level residency restrictions, a rationale that may not survive if federal rescheduling or descheduling occurs.

Why This Matters

Montana's residency requirement affects approximately $300 million in annual cannabis sales and determines who can participate in one of the nation's fastest-growing state markets. The state issued 447 active adult-use licenses and 261 medical cannabis licenses as of August 2026, according to Montana Department of Revenue data. The new residency mandate directly impacts multi-state operators seeking Montana market entry, existing licensees with out-of-state ownership stakes, and Montana residents competing for limited license opportunities in jurisdictions with local caps. For patients, the policy shapes dispensary competition, product diversity, and pricing. Montana's medical program served approximately 28,000 registered patients as of mid-2026, while adult-use sales have grown 47% year-over-year since the first recreational dispensaries opened in January 2022. Residency restrictions may limit capital investment from institutional sources, potentially constraining facility expansion, product innovation, and market professionalization. The legal strategy carries national significance. Montana becomes the latest state to use federal prohibition as a shield against Commerce Clause challenges, following similar approaches in Maine, Alaska, and Washington during their early implementation years. If Montana's rationale withstands judicial scrutiny, other states may adopt comparable residency mandates. Conversely, a successful legal challenge could force Montana and peer states to open their markets to interstate competition, fundamentally reshaping regional cannabis economies.

Background and History: Montana's Path to Regulated Cannabis

Montana's cannabis regulatory journey spans two decades, from medical legalization through voter-approved adult-use and now residency-based market restrictions.

Medical Cannabis Initiative (2004)

Montana voters approved Initiative 148 in November 2004 with 62% support, establishing one of the nation's early medical marijuana programs. The law permitted patients with debilitating conditions to possess up to one ounce and cultivate six plants, with physician certification required. The statute created a caregiver model allowing individuals to assist up to three patients, but included no commercial licensing framework or state regulatory agency. Between 2004 and 2009, Montana's medical program operated with minimal state oversight. Caregivers registered directly with the Montana Department of Public Health and Human Services, but no inspections, testing requirements, or product standards existed. The program served fewer than 5,000 patients through 2009.

Rapid Expansion and Legislative Backlash (2009-2011)

Medical cannabis businesses proliferated across Montana between 2009 and 2011 following a U.S. Department of Justice memo suggesting federal prosecutors would deprioritize state-compliant medical marijuana cases. Patient enrollment surged from approximately 4,000 in early 2009 to more than 30,000 by mid-2011. Storefronts opened in Billings, Missoula, Great Falls, and Helena, operating under the caregiver provision despite serving hundreds of patients each. The Montana Legislature responded in 2011 with Senate Bill 423, which Governor Brian Schweitzer allowed to become law without his signature. SB 423 repealed the caregiver provision, prohibited storefront dispensaries, banned compensation for providing medical cannabis, and restricted providers to serving three patients maximum. The law effectively dismantled Montana's commercial medical cannabis infrastructure. Legal challenges immediately followed. Montana Cannabis Industry Association v. State of Montana reached the Montana Supreme Court, which upheld most provisions in 2012. Patient enrollment dropped to fewer than 8,000 by 2013 as providers exited the market.

Regulatory Rebuild (2016-2017)

Initiative 182, approved by voters in November 2016 with 57% support, repealed SB 423's most restrictive provisions. The measure eliminated the three-patient limit, allowed providers to receive compensation, and permitted storefront dispensaries under local zoning. The Montana Legislature codified the changes in House Bill 422 during the 2017 session, establishing the first comprehensive regulatory framework under the Montana Department of Public Health and Human Services. HB 422 created distinct license types for cultivation, manufacturing, and dispensary operations. The law imposed no residency requirements, allowing out-of-state investment and ownership. Multi-state operators including Columbia Care and Curaleaf entered Montana between 2017 and 2019, acquiring existing medical providers and opening new facilities.

Adult-Use Legalization (2020)

Montana voters approved Constitutional Initiative 118 and companion statute Initiative 190 in November 2020. CI-118 amended the Montana Constitution to establish that individuals 21 and older could possess and consume cannabis, while I-190 created the regulatory structure for adult-use sales. The measures passed with 57% and 56% support respectively, outperforming presidential candidate Joe Biden's 40% vote share in Montana. I-190 imposed a 20% tax on adult-use cannabis sales at the retail level, directed revenue to conservation programs, veterans services, substance abuse treatment, and local governments, and tasked the Montana Department of Revenue with regulatory implementation. The law established a tiered licensing structure with separate permits for cultivation, manufacturing, dispensary, and testing operations. Critically, I-190 included no residency requirements for license applicants.

Implementation and Market Launch (2021-2022)

The Montana Department of Revenue's Cannabis Control Division opened adult-use license applications in June 2021. The agency granted priority to existing medical licensees, allowing them to add adult-use endorsements to current permits. The first adult-use sales occurred on January 1, 2022, with approximately 120 dispensaries operational statewide. Adult-use revenue reached $56 million in the first six months of 2022, exceeding initial projections. The Montana Department of Revenue collected $11.2 million in excise taxes during that period. Multi-state operators expanded aggressively, with Columbia Care operating eight dispensaries, Curaleaf running five locations, and Green Peak Industries (later acquired by Trulieve) controlling seven stores by year-end 2022.

Residency Debate Emerges (2023-2025)

Montana legislators introduced residency requirement bills during the 2023 session. House Bill 565 proposed requiring 51% Montana resident ownership for all cannabis licenses, while Senate Bill 442 sought 100% resident ownership mandates. Both bills failed in committee, with opponents citing Commerce Clause concerns and existing licensee objections. The Montana Cannabis Guild, representing approximately 80 Montana-based operators, lobbied for residency restrictions throughout 2023 and 2024. The organization argued that multi-state operators used superior capital access to dominate prime retail locations, undercut pricing, and consolidate market share. According to guild data, MSO-affiliated dispensaries controlled approximately 38% of Montana's adult-use sales volume by mid-2024 despite representing only 22% of licensed locations. The Montana Department of Revenue initiated rulemaking proceedings in March 2025 to consider residency requirements. The agency held public comment periods in April and June 2025, receiving more than 400 submissions. The Cannabis Control Division published draft regulations in December 2025 proposing 100% Montana residency requirements for all license types.

Final Rule Adoption (September 2026)

The Montana Department of Revenue adopted Administrative Rule 42.39.301 on September 15, 2026, effective immediately for new license applications and within 180 days for existing licensees with non-resident ownership. The rule requires all individuals with ownership interests of 10% or greater to demonstrate Montana residency through driver's license, voter registration, or property tax records showing 183 days of physical presence in the preceding 12 months. The Cannabis Control Division's statement accompanying the rule cited 21 U.S.C. § 812's Schedule I classification as legal justification. The agency argued that federal prohibition prevents interstate cannabis commerce, eliminating dormant Commerce Clause protections that typically prohibit state residency requirements in lawful industries. The Montana Attorney General's office provided a legal opinion supporting this interpretation in August 2026.

Key Players

Montana Department of Revenue Cannabis Control Division

The Cannabis Control Division administers Montana's medical and adult-use programs, including license issuance, compliance inspections, and enforcement actions. Director Brendan Beatty, appointed in 2023, oversees approximately 35 staff members responsible for regulating 708 active licenses statewide. The division operates on a budget of $4.2 million annually, funded entirely through licensing fees and application charges. Beatty previously served as deputy director of the Montana Department of Public Health and Human Services and worked as a policy advisor during I-190's implementation.

Montana Cannabis Guild

The Montana Cannabis Guild represents locally-owned cannabis businesses and advocated for residency requirements throughout 2023-2025. The organization claims approximately 80 member companies operating 140 licensed facilities. Executive Director Sarah Chen, a former Montana state legislator, led the guild's lobbying efforts. The guild commissioned economic analysis from University of Montana researchers arguing that locally-owned businesses retain more revenue in-state and provide higher wage employment compared to MSO-affiliated operations.

Multi-State Operators

Trulieve, Curaleaf, Columbia Care (acquired by Cresco Labs in 2023), and Ayr Wellness operate Montana dispensaries and cultivation facilities through subsidiary entities. These companies collectively control approximately 35 licensed locations across Montana. Trulieve operates the state's largest cultivation facility, a 50,000-square-foot indoor operation in Missoula producing approximately 800 pounds monthly. MSO representatives argued during public comment periods that residency requirements would reduce capital investment, limit product innovation, and potentially increase consumer prices.

Montana Attorney General Austin Knudsen

Attorney General Knudsen, elected in 2020, provided the legal opinion supporting the Cannabis Control Division's authority to impose residency requirements. His office's August 2026 memorandum concluded that federal Schedule I status creates an exception to Commerce Clause restrictions, allowing Montana to limit licenses to residents. Knudsen previously served in the Montana House of Representatives and voted against medical cannabis expansion bills during his legislative tenure.

National Cannabis Industry Association

The National Cannabis Industry Association, representing more than 1,500 cannabis businesses nationwide, submitted public comments opposing Montana's residency requirement. NCIA's legal counsel argued that the dormant Commerce Clause applies regardless of federal prohibition status and cited Rocky Mountain Farmers Union v. Corey, a 2013 Tenth Circuit decision invalidating Colorado's renewable energy residency preferences. The organization has not announced litigation plans but indicated it is monitoring Montana's implementation.

Legal and Regulatory Framework

Montana's residency requirement rests on state constitutional authority, statutory implementation of voter initiatives, and administrative rulemaking under the Montana Administrative Procedure Act.

Constitutional Foundation

Constitutional Initiative 118, codified as Article II, Section 36 of the Montana Constitution, establishes that adults 21 and older may possess and consume cannabis. The provision grants the Montana Legislature authority to regulate cannabis commerce, providing the statutory foundation for licensing requirements. The constitutional amendment includes no residency language, leaving such determinations to legislative or administrative action.

Statutory Authority

Initiative 190, codified at Montana Code Annotated § 16-12-101 et seq., creates Montana's adult-use regulatory structure. Section 16-12-301 grants the Montana Department of Revenue authority to "adopt rules necessary to implement and administer" the cannabis program, including "qualifications for licensure." The statute does not explicitly authorize or prohibit residency requirements, creating ambiguity that the Cannabis Control Division resolved through administrative rulemaking. Montana's medical cannabis program operates under MCA § 50-46-101 et seq., with parallel licensing provisions. The Cannabis Control Division applied identical residency requirements to medical licenses through coordinated rulemaking.

Administrative Rule 42.39.301

Administrative Rule 42.39.301, adopted September 15, 2026, requires that "all individuals holding ownership interests of ten percent or greater in any cannabis license applicant or licensee must demonstrate Montana residency." The rule defines residency as physical presence in Montana for 183 days during the 12 months preceding application, evidenced by:

• Montana driver's license or state identification card issued at least 12 months prior
• Montana voter registration active for at least 12 months
• Montana property tax records showing ownership or lease of Montana real property
• Montana income tax returns for the preceding tax year showing Montana as primary residence

The rule applies immediately to new applications submitted after September 15, 2026. Existing licensees with non-resident ownership must achieve compliance by March 15, 2027, either through ownership restructuring or license surrender.

Federal Prohibition as Legal Shield

The Cannabis Control Division's legal rationale relies on 21 U.S.C. § 812, which classifies cannabis as a Schedule I controlled substance under the Controlled Substances Act. The agency argues that federal prohibition prevents lawful interstate cannabis commerce, eliminating the "substantial effect on interstate commerce" required to trigger dormant Commerce Clause scrutiny. This interpretation follows legal theories advanced in Maine and Alaska, where residency requirements have not faced successful judicial challenges as of September 2026. The U.S. Supreme Court has not directly addressed whether dormant Commerce Clause protections apply to state-legal cannabis markets operating in violation of federal law. The closest precedent, Granholm v. Heald (2005), invalidated state wine shipping laws that discriminated against out-of-state producers, but involved a lawful product under federal law. Cannabis prohibition creates legal ambiguity that Montana seeks to exploit.

Potential Legal Vulnerabilities

Legal experts have identified several challenges to Montana's approach. First, the dormant Commerce Clause may apply even to federally prohibited products if states create markets that function as interstate commerce. Second, the Privileges and Immunities Clause of Article IV, Section 2 of the U.S. Constitution protects citizens' rights to pursue livelihoods across state lines, potentially prohibiting residency-based license restrictions regardless of federal prohibition. Third, if the Drug Enforcement Administration reschedules cannabis to Schedule III or Congress enacts federal legalization, Montana's legal justification evaporates. The Montana rule also faces potential state constitutional challenges. The Montana Constitution's equal protection provisions may prohibit discrimination against out-of-state residents absent compelling state interest. Montana courts apply intermediate scrutiny to residency classifications, requiring that restrictions substantially further important governmental objectives.

State-by-State Comparison of Residency Requirements

Montana joins a minority of cannabis states imposing strict residency requirements, while most mature markets allow out-of-state ownership with varying restrictions.

State	Residency Requirement	Ownership Threshold	Implementation Date	Legal Status
Montana	100% resident ownership	10% or greater interest	September 2026	Active, no litigation filed
Alaska	100% resident ownership	Any ownership interest	February 2016	Active, survived administrative challenges
Maine	51% resident ownership	Controlling interest	October 2020	Active, no successful legal challenges
Washington	51% resident ownership (initial); repealed 2022	Majority interest	July 2014 - June 2022	Repealed by legislature
Colorado	None since 2019	N/A	Eliminated January 2019	Open market
California	None	N/A	N/A	Open market
Michigan	None	N/A	N/A	Open market
Illinois	None; social equity preferences for residents	N/A	January 2020	Open with equity scoring
New York	None; social equity preferences for residents	N/A	December 2022	Open with equity scoring

Alaska's Strict Approach

Alaska maintains the nation's most restrictive residency requirement, mandating 100% Alaska resident ownership for all cannabis licenses under 3 AAC 306.020. The Alaska Marijuana Control Board has enforced this requirement since the first licenses issued in February 2016. No successful legal challenges have emerged, though the small market size (approximately $30 million annual sales) may reduce litigation incentives. Alaska's population of 733,000 creates limited opportunities for large-scale cannabis operations, potentially explaining the lack of MSO interest in challenging the restriction.

Maine's Majority-Resident Model

Maine requires 51% resident ownership for adult-use cannabis licenses under 28-B M.R.S. § 202. The Maine Office of Cannabis Policy implemented this requirement when adult-use sales began in October 2020. Medical cannabis licenses face no residency restrictions, creating a two-tier system. Maine's approach allows out-of-state capital participation while ensuring resident control of licensed entities. Approximately 15% of Maine's 350 adult-use licensees have disclosed out-of-state minority investors, according to Office of Cannabis Policy data.

Washington's Reversal

Washington initially required 51% resident ownership when adult-use sales launched in July 2014 under RCW 69.50.331. The Washington State Liquor and Cannabis Board enforced this requirement through 2022, but the legislature repealed the restriction in House Bill 1210, effective June 2022. Sponsors cited difficulty attracting capital investment, competitive disadvantages compared to neighboring Oregon's open market, and legal vulnerability following federal hemp legalization under the 2018 Farm Bill. Washington's reversal demonstrates that residency requirements face ongoing political pressure as markets mature.

Open Markets in Colorado, California, and Michigan

Colorado eliminated its initial two-year residency requirement in January 2019, opening the market to out-of-state investors and MSO expansion. California never imposed residency restrictions, resulting in heavy MSO presence and approximately $5.2 billion in annual sales as of 2025. Michigan similarly allows unrestricted out-of-state ownership, contributing to rapid market growth exceeding $3 billion annually. These open markets demonstrate alternative regulatory approaches prioritizing capital access and market competition over local ownership protection.

Market and Business Implications

Montana's residency requirement will reshape competitive dynamics, restrict capital access, and potentially increase consolidation among existing Montana-based operators.

Impact on Multi-State Operators

MSO-affiliated entities must divest Montana operations or restructure ownership to achieve compliance by the March 15, 2027 deadline. Trulieve's Montana subsidiary, operating eight dispensaries and the state's largest cultivation facility, faces the most significant impact. The company has not publicly disclosed its compliance strategy, but options include selling Montana assets to resident buyers, converting to management services agreements with resident-owned entities, or legal challenges to the rule. Industry analysts estimate Montana MSO assets at $80-120 million in aggregate value based on comparable transactions in similar-sized markets. The compressed timeline for compliance may depress sale prices if multiple MSOs simultaneously seek buyers from Montana's limited pool of qualified resident purchasers. Curaleaf, operating five Montana dispensaries, announced in an October 2026 investor call that it is "evaluating strategic alternatives" for Montana operations. Cresco Labs, which acquired Columbia Care's Montana assets in 2023, indicated it may pursue legal challenges while simultaneously exploring divestiture options.

Capital Access Constraints

Montana cannabis businesses face significant capital access challenges due to federal prohibition, which prevents traditional bank lending and creates reliance on private equity, venture capital, and high-interest debt. Residency requirements further restrict capital sources by eliminating national institutional investors and multi-state private equity funds. Montana-based operators seeking expansion capital must now source funding exclusively from Montana residents or restructure to comply with the 10% ownership threshold. This constraint particularly affects cultivation and manufacturing operations requiring substantial capital for facility construction, equipment purchases, and working capital during production cycles. The Montana Bankers Association has not altered its guidance discouraging member banks from providing cannabis banking services, leaving most operators dependent on credit unions and out-of-state financial institutions. Residency requirements compound this challenge by eliminating cross-collateralization opportunities where MSOs pledge assets across multiple states to secure financing.

Pricing and Consumer Impact

Economic analysis of residency requirements in Alaska and Maine suggests modest price increases of 3-8% following implementation, according to research from the Marijuana Policy Project. Reduced competition from MSO exit may allow remaining operators to increase margins, though Montana's relatively open licensing system (no statewide caps on dispensary licenses) may limit pricing power. Montana's adult-use market averaged $28 per gram for flower, $45 per gram for concentrates, and $25 per 100mg edible product as of August 2026, according to Cannabis Benchmarks pricing data. These prices sit approximately 15% below Colorado and 8% above Washington, suggesting moderate competitive pressure. If residency requirements reduce the number of licensed operators through MSO exit and reduced new entry, prices may converge toward Washington levels. Patient access in Montana's medical program faces particular concern. Medical cannabis patients, numbering approximately 28,000 as of mid-2026, rely on lower-priced medical products exempt from the 20% adult-use tax. If MSO-operated medical dispensaries close or convert to adult-use-only operations, patients in rural areas may lose access to nearby sources. Montana's medical program allows patients to cultivate their own supply, providing a safety valve, but many patients lack the knowledge, space, or physical ability to grow cannabis.

Social Equity Considerations

Montana's cannabis regulations include no social equity provisions, license application scoring preferences, or technical assistance programs for communities disproportionately impacted by cannabis prohibition. The residency requirement operates as a blunt instrument benefiting all Montana residents equally, without targeting individuals most harmed by prior enforcement. Advocates including the Montana ACLU criticized the residency rule during public comment periods for failing to address racial disparities in Montana's cannabis arrest records. According to FBI Uniform Crime Reporting data, Black Montanans were arrested for cannabis possession at 2.8 times the rate of white residents between 2015 and 2020, despite similar usage rates. The residency requirement provides no specific benefits to these communities and may entrench existing licensees who entered the market with capital accumulated during prohibition.

Local Government Revenue

Montana's adult-use cannabis tax structure directs revenue to state programs and local governments where sales occur. Counties and municipalities receive a combined 10.5% of the 20% retail excise tax, generating approximately $18 million for local governments in fiscal year 2025. Residency requirements may reduce this revenue if MSO exit causes temporary dispensary closures or if reduced competition lowers overall sales volume. Missoula County, Montana's second-most-populous jurisdiction, collected $2.1 million in cannabis tax revenue in fiscal 2025, funding road maintenance, public health programs, and open space acquisition. County officials expressed concern during public comment periods that MSO departure could reduce revenue, though they took no formal position on the residency requirement.

What Experts Say

Legal scholars, industry analysts, and policy advocates offer divergent assessments of Montana's residency requirement, its legal foundation, and market consequences. Robert Mikos, professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," said in a September 2026 interview with Marijuana Moment that Montana's legal theory faces "significant but not insurmountable" challenges. According to Mikos, the dormant Commerce Clause question remains unsettled in cannabis contexts, and Montana's approach may survive judicial review if courts determine that federal prohibition eliminates interstate commerce protections. However, Mikos noted that the Privileges and Immunities Clause presents a separate barrier that Montana's rule may not overcome. Hilary Bricken, attorney at Harris Bricken and chair of the firm's cannabis practice group, told Cannabis Business Times that residency requirements represent "short-term protectionism with long-term costs." According to Bricken, Montana operators may benefit from reduced competition initially, but capital constraints will limit market development compared to open markets in Colorado and Michigan. Bricken predicted that Montana's rule would face legal challenges within six months of the March 2027 compliance deadline. Andrew Kline, former federal prosecutor and partner at Perkins Coie, provided analysis to Politico in September 2026 suggesting that potential federal rescheduling creates "a ticking clock" for Montana's legal justification. According to Kline, if the Drug Enforcement Administration moves cannabis to Schedule III as proposed in the DEA's Notice of Proposed Rulemaking published in May 2024, Montana's argument that federal prohibition eliminates Commerce Clause protections becomes untenable. Kline noted that Schedule III substances including ketamine and anabolic steroids move in interstate commerce under DEA oversight, creating precedent for lawful cannabis commerce that would undermine residency restrictions. Morgan Fox, political director for the National Organization for the Reform of Marijuana Laws, said in a statement that Montana's approach "prioritizes incumbent business interests over patient access and market efficiency." According to Fox, residency requirements in Alaska and Maine have not demonstrably improved patient outcomes or reduced prices, and Montana's rule may similarly fail to deliver promised benefits to consumers. Economists at the University of Montana's Bureau of Business and Economic Research produced analysis commissioned by the Montana Cannabis Guild finding that locally-owned cannabis businesses retain approximately 68% of revenue in-state compared to 41% for MSO-affiliated operations. The research, released in July 2025, examined tax records, employment data, and supply chain patterns. However, critics noted that the analysis did not account for MSO investments in facility construction, equipment purchases from Montana vendors, or employment of Montana residents in cultivation and retail operations.

What's Next

Montana's residency requirement faces a March 15, 2027 compliance deadline for existing licensees, potential legal challenges, and ongoing political debate as the 2027 legislative session approaches.

Immediate Timeline

The Cannabis Control Division will process new license applications under the residency requirement beginning in October 2026. The agency reported receiving 23 new applications in the first two weeks following rule adoption, compared to a typical monthly volume of 15-20 applications. All new applicants must demonstrate Montana residency before license issuance. Existing licensees with non-resident ownership exceeding 10% must submit compliance plans to the Cannabis Control Division by December 15, 2026. These plans must detail how the licensee will achieve full resident ownership by March 15, 2027, through ownership restructuring, buyouts, or voluntary license surrender. The division will review plans and may grant 60-day extensions in cases demonstrating good-faith compliance efforts. MSO-affiliated entities face the most compressed timeline. Trulieve, Curaleaf, and Cresco Labs must negotiate sales, identify qualified Montana buyers, complete due diligence, and obtain Cannabis Control Division approval for ownership transfers within approximately five months. Industry observers expect a wave of transactions between December 2026 and February 2027 as the deadline approaches.

Legal Challenge Scenarios

The National Cannabis Industry Association, multi-state operators, and potentially individual licensees may file legal challenges in Montana state court or federal district court. State court challenges would likely invoke the Montana Constitution's equal protection and due process provisions, arguing that residency requirements lack rational basis or violate economic liberty protections. Federal challenges would center on the dormant Commerce Clause and Privileges and Immunities Clause. If litigation proceeds, Montana courts would likely address state constitutional claims first under the doctrine of constitutional avoidance. The Montana Supreme Court has not previously addressed cannabis residency requirements, creating uncertainty about the outcome. Federal courts might decline to hear challenges under the doctrine of abstention, deferring to state courts on state law questions. Legal challenges typically require 18-36 months to reach final resolution, extending beyond the March 2027 compliance deadline. Plaintiffs would likely seek preliminary injunctions to pause enforcement during litigation. The Cannabis Control Division has indicated it will vigorously defend the rule, with the Montana Attorney General's office providing representation.

2027 Legislative Session

The Montana Legislature convenes in January 2027 for its biennial 90-day session. Legislators may introduce bills to codify, modify, or repeal the residency requirement. The Montana Cannabis Guild has indicated it will lobby for statutory codification to strengthen the rule's legal foundation. Conversely, MSO-aligned interests and the Montana Chamber of Commerce may seek repeal or modification to a less restrictive majority-resident ownership model similar to Maine's approach. Governor Greg Gianforte, elected in 2020 and facing reelection in 2028, has not publicly stated a position on residency requirements. Gianforte opposed I-190 during the 2020 campaign but has not sought to undermine implementation as governor. His position on potential legislative changes may prove decisive, as Montana governors wield line-item veto authority over appropriations bills and can veto substantive legislation.

Federal Rescheduling Impact

The Drug Enforcement Administration's proposed rescheduling of cannabis to Schedule III remains pending as of September 2026. The DEA published a Notice of Proposed Rulemaking in May 2024 following a recommendation from the U.S. Department of Health and Human Services. The agency held public hearings in December 2024 and extended the comment period through March 2025, receiving more than 43,000 submissions. If the DEA finalizes Schedule III rescheduling, Montana's legal justification for residency requirements faces immediate challenge. Schedule III substances move in lawful interstate commerce under DEA registration and oversight, eliminating the federal prohibition rationale Montana relies upon. The Cannabis Control Division would likely defend the rule by arguing that state police powers allow residency requirements regardless of federal scheduling, but this argument faces significant legal obstacles under dormant Commerce Clause precedent. Congressional legislation including the SAFER Banking Act and various legalization bills remain stalled as of September 2026. If Congress enacts federal legalization or removes cannabis from the Controlled Substances Act entirely, Montana's residency requirement becomes legally vulnerable and likely indefensible under existing Commerce Clause doctrine.

Market Evolution

Montana's cannabis market will likely experience consolidation among resident-owned operators as MSO assets become available. Well-capitalized Montana operators including Lionheart Cannabis, Emerald Peaks, and Montana Buds may acquire MSO facilities, increasing their market share. Alternatively, new entrants with Montana resident ownership may purchase divested assets, potentially increasing overall competition despite MSO exit. The Cannabis Control Division projects that Montana's adult-use market will reach $400 million in annual sales by 2028, up from approximately $300 million in 2026. This growth trajectory assumes continued license issuance and market expansion, but residency requirements may constrain growth if capital access limitations prevent facility expansion and product innovation.

Further Reading

• Montana Department of Revenue Cannabis Control Division: https://mtrevenue.gov/cannabis/ — Official regulatory agency website with licensing information, rules, and compliance guidance
• Montana Code Annotated Title 16, Chapter 12: https://leg.mt.gov/bills/mca/title_0160/chapter_0120/parts_index.html — Complete statutory text of Montana's adult-use cannabis law
• Administrative Rule 42.39.301: https://rules.mt.gov/gateway/ruleno.asp?RN=42.39.301 — Full text of residency requirement regulation
• Initiative 190 (2020): https://sosmt.gov/elections/2020-ballot-issues/ — Original ballot language approved by voters
• Montana Cannabis Guild: https://montanacannabis.org — Industry association representing locally-owned operators
• Montana Attorney General Opinion on Residency Requirements (August 2026): https://doj.mt.gov/ago/opinions/ — Legal analysis supporting Cannabis Control Division